Belite Bio Inc ADR BLTE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
-
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024
-
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
-
Belite Bio to Participate in Three Upcoming Investor Conferences
-
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
-
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
-
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $46.55
- Day Range
- $45.96–47.00
- 52-Week Range
- $28.51–50.66
- Bid/Ask
- $43.36 / $49.15
- Market Cap
- $1.44 Bil
- Volume/Avg
- 36,061 / 30,880
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 20
- Website
- https://www.belitebio.com
Valuation
|
Metric
|
BLTE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 12.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BLTE
|
|---|---|
Quick Ratio | — |
Current Ratio | — |
Interest Coverage | — |
Quick Ratio
BLTE
Profitability
|
Metric
|
BLTE
|
|---|---|
Return on Assets (Normalized) | −40.80% |
Return on Equity (Normalized) | −43.04% |
Return on Invested Capital (Normalized) | −42.94% |
Return on Assets
BLTE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jldywsvwm | Bqxl | $524.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wvfrcqgp | Yfpbjb | $120.0 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Kfqtdglmz | Rcjgby | $115.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rqngrxsm | Hqmszqx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Mzyljnz | Wbd | $32.4 Bil | |||
| BioNTech SE ADR
BNTX
| Mpvcgphz | Rcck | $28.2 Bil | |||
| Moderna Inc
MRNA
| Sywglhbhr | Stzq | $25.7 Bil | |||
| United Therapeutics Corp
UTHR
| Qgqwlfj | Dgpc | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ntmjtdkl | Lzkscft | $13.4 Bil | |||
| Incyte Corp
INCY
| Tmmsrcccl | Xqxglk | $12.7 Bil |
United States